AmerisourceBergen Reports Revenue of $21.9 Billion and Adjusted Diluted EPS from Continuing Operations of $0.73

  AmerisourceBergen Reports Revenue of $21.9 Billion and Adjusted Diluted EPS
  from Continuing Operations of $0.73

  Company Now Expects Fiscal Year 2013 Adjusted Diluted EPS from Continuing
                  Operations in the Range of $3.06 to $3.11

Business Wire

VALLEY FORGE, Pa. -- July 24, 2013

AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal
year third quarter ended June 30, 2013, adjusted diluted earnings per share
from continuing operations were $0.73, which excludes LIFO expense of $122.1
million and warrant expense of $35.8 million. On the basis of U.S. generally
accepted accounting principles (GAAP), diluted earnings per share from
continuing operations were $0.27 in the quarter. Revenue in the quarter was
$21.9 billion, up 13.3 percent. The Company also narrowed the range of its
expectations for the full fiscal year 2013 adjusted diluted earnings per share
from continuing operations to $3.06 to $3.11 from its previous range of $3.04
to $3.14.

In the tables that follow, we present our GAAP results as well as a
reconciliation of GAAP income from continuing operations to non-GAAP adjusted
income from continuing operations for the June quarter and the first nine
months of fiscal 2013. Fiscal 2012 results are presented on a GAAP basis only,
and include a LIFO expense of $4.7 million in the June quarter, and $11.4
million for the first nine months of fiscal 2012. There was no warrant expense
in fiscal 2012.

“In our June quarter, AmerisourceBergen delivered solid performance and made
significant progress on strategic initiatives,” said Steven H. Collis,
AmerisourceBergen President and Chief Executive Officer. “We completed two
previously announced divestitures, obtained the required regulatory approvals
on certain aspects of our new strategic long-term relationship with Walgreen
Co. and Alliance Boots GmbH, and have begun to prepare our network for the
onboarding of the new Walgreens distribution contract in September. In
addition, we recently enhanced our financial flexibility by increasing the
borrowing capacity of our revolver and our securitization programs. Not only
are we on track to meet our objectives for the full fiscal year, but we have
taken important steps to strengthen our ability to generate sustainable long
term growth that benefits all of our stakeholders.”

The comments below compare adjusted results for fiscal 2013 to GAAP results
for fiscal 2012.

Summary of Quarterly Results

  *Revenue: Revenue was $21.9 billion in the third quarter of fiscal 2013, a
    13.3 percent increase over the same quarter in the previous fiscal year,
    driven by a 16 percent increase in AmerisourceBergen Drug Corporation
    (ABDC) revenue, and a 5 percent increase in AmerisourceBergen Specialty
    Group (ABSG) revenue.
  *Gross Profit: Gross profit in the fiscal 2013 third quarter was $684.5
    million, a 2.5 percent increase over the year-ago same period, driven by
    contributions from one incremental month of World Courier results in the
    third quarter of fiscal 2013, offset by lower contributions from our
    Pharmaceutical Distribution Segment. The World Courier acquisition
    anniversaried in May 2013. Gross profit as a percentage of revenue
    decreased 34 basis points to 3.12 percent over the same period in the
    previous year.
  *Operating Expenses: For the third quarter of fiscal 2013, operating
    expenses were $392.0 million compared with $343.5 million in the prior
    fiscal year’s third quarter, a 14.1 percent increase. The increase in
    operating expenses was due primarily to World Courier, and deal related
    transaction costs, primarily related to professional fees relating to the
    Walgreens and Alliance Boots transaction. In the fiscal third quarter of
    2013, operating expenses as a percentage of revenue were 1.79 percent, up
    1 basis point from the same period in the previous fiscal year.
  *Operating Income: In the fiscal 2013 third quarter, operating income
    decreased 9.8 percent to $292.5 million, due to lower gross profit in our
    Pharmaceutical Distribution segment, and deal related transaction costs.
    Operating income as a percentage of revenue decreased 34 basis points to
    1.34 percent in the period compared with the previous year’s third
    quarter.
  *Tax Rate: The adjusted effective tax rate for the third quarter of fiscal
    2013 was 37.4 percent, compared to 37.7 percent in the previous fiscal
    year’s third quarter.
  *Earnings Per Share: Adjusted diluted earnings per share from continuing
    operations were down 1.4 percent to $0.73 in the third quarter of fiscal
    2013 compared to $0.74 in the previous fiscal year’s third quarter. While
    income from continuing operations decreased 9.9 percent, adjusted diluted
    earnings per share only decreased 1.4 percent due to the 7.8 percent
    reduction in diluted weighted average shares outstanding.
  *Shares Outstanding: Diluted weighted average shares outstanding for the
    third quarter of fiscal year 2013 were 235.7 million, down 20.1 million
    shares from the previous fiscal year’s third quarter due primarily to
    share repurchases, net of option exercises over the last twelve months.

Segment Discussion

The Pharmaceutical Distribution segment includes both AmerisourceBergen Drug
Corporation and AmerisourceBergen Specialty Group. Other includes
AmerisourceBergen Consulting Services (ABCS) and World Courier. The results of
operations from AndersonBrecon and AmerisourceBergen Canada Corporation, both
of which were sold in the third quarter of fiscal 2013, are reported as
discontinued operations.

Pharmaceutical Distribution Segment

In the third fiscal quarter of 2013, Pharmaceutical Distribution revenues were
$21.5 billion, an increase of 13 percent compared to the same quarter in the
prior year. ABDC revenues increased 16 percent, due primarily to the
previously announced contract with our large PBM customer, and a smaller
negative impact from brand to generic conversions. ABSG revenues increased 5
percent, which was driven by strong performance in our blood products, vaccine
and physician office distribution businesses partially offset by a revenue
decline in our oncology business. Intrasegment revenues between ABDC and ABSG
have been eliminated in the presentation of total Pharmaceutical Distribution
revenue. Total intrasegment revenues were $810.1 million and $673.3 million in
the quarters ended June 30, 2013 and 2012, respectively.

Operating income of $287.2 million in the June quarter of fiscal 2013
decreased 7 percent compared to the same period in the previous year driven by
a 28 basis point decline in operating margin due to a shift in customer mix
towards lower margin business in both ABDC and ABSG, disappointing performance
in our oncology business, and fewer new generic launches to offset those
impacts.

Other

Revenues in Other increased 17% and were $466.7 million in the third quarter
of fiscal 2013, including significant contributions from an incremental month
of World Courier operating results compared to the prior year. Gross profit
and expenses also increased compared to the prior year due primarily to
contributions from World Courier. Operating income increased significantly to
$25.1 million in the third quarter of 2013, with the majority of the increase
provided by improved World Courier performance.

Fiscal Year 2013 Expectations

“Looking ahead, the Company now expects adjusted diluted earnings per share
from continuing operations in fiscal year 2013 to be in the range of $3.06 to
$3.11,” said Steven H. Collis, AmerisourceBergen President and Chief Executive
Officer. “We continue to expect revenue growth in the 11 percent to 13 percent
range; operating income decline in the 3 percent to 5 percent range; an
operating margin decline in the range of 24 to 29 basis points; and free cash
flow in the range of $100 million to $200 million, which includes capital
expenditures of approximately $240 million. We have repurchased $401 million
in shares through June 30, 2013, in line with our expectations for the full
fiscal year.”

Conference Call

The Company will host a conference call to discuss the results at 11:00 a.m.
Eastern Time on July 24, 2013.

Participating in the conference call will be:

Steven H. Collis, President & Chief Executive Officer
Tim G. Guttman, Senior Vice President & Chief Financial Officer

The dial-in number for the live call will be (612) 288-0329. No access code is
required for the call. The live call will also be webcast via the Company’s
website at www.amerisourcebergen.com. Users are encouraged to log on to the
webcast approximately 10 minutes in advance of the scheduled start time of the
call.

Replays of the call will be made available via telephone and webcast. A replay
of the webcast will be posted on www.amerisourcebergen.com approximately two
hours after the completion of the call and will remain available for thirty
days. The telephone replay will also be available approximately two hours
after the completion of the call and will remain available for seven days. To
access the telephone replay from within the US, dial (800) 475-6701. From
outside the US, dial (320) 365-3844. The access code for the replay is 297735.

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both healthcare providers and pharmaceutical manufacturers in the
pharmaceutical supply channel, the Company provides drug distribution and
related services designed to reduce costs and improve patient outcomes.
AmerisourceBergen's service solutions range from niche premium logistics and
pharmaceutical packaging to reimbursement and pharmaceutical consulting
services. With over $80 billion in annualized revenue, AmerisourceBergen is
headquartered in Valley Forge, PA, and employs approximately 13,000 people.
AmerisourceBergen is ranked #32 on the Fortune 500 list. For more information,
go to www.amerisourcebergen.com.

Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this press release are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. Words such as
“expect,” “likely,” “outlook,” “forecast,” “would,” “could,” “should,” “can,”
“will,” “project,” “intend,” “plan,” “continue,” “sustain,” “synergy,” “on
track,” “believe,” “seek,” “estimate,” “anticipate,” “may,” ”possible,”
“assume,” variations of such words, and similar expressions are intended to
identify such forward-looking statements. These statements are based on
management's current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance and
are based on assumptions that could prove incorrect or could cause actual
results to vary materially from those indicated. Among the factors that could
cause actual results to differ materially from those projected, anticipated or
implied are the following: changes in pharmaceutical market growth rates; the
loss of one or more key customer or supplier relationships; changes in
customer mix; customer delinquencies, defaults or insolvencies; supplier
defaults or insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract or
other dispute with customers or suppliers; federal and state government
enforcement initiatives to detect and prevent suspicious orders of controlled
substances and the diversion of controlled substances; qui tam litigation for
alleged violations of fraud and abuse laws and regulations and/or any other
laws and regulations governing the marketing, sale, purchase, and/or
dispensing of pharmaceutical products or services and any related litigation,
including shareholder derivative lawsuits; changes in federal and state
legislation or regulatory action affecting pharmaceutical product pricing or
reimbursement policies, including under Medicaid and Medicare; changes in
regulatory or clinical medical guidelines and/or labeling for the
pharmaceutical products we distribute, including certain anemia products;
price inflation in branded pharmaceuticals and price deflation in generics;
greater or less than anticipated benefit from launches of the generic versions
of previously patented pharmaceutical products; significant breakdown or
interruption of our information technology systems; our inability to realize
the anticipated benefits of the implementation of an enterprise resource
planning (ERP) system; interest rate and foreign currency exchange rate
fluctuations; risks associated with international business operations,
including non-compliance with the U.S. Foreign Corrupt Practices Act,
anti-bribery laws and economic sanctions and import laws and regulations;
economic, business, competitive and/or regulatory developments outside of the
United States; risks associated with the strategic, long-term relationship
among Walgreen Co., Alliance Boots GmbH, and AmerisourceBergen, the occurrence
of any event, change or other circumstance that could give rise to the
termination, cross-termination or modification of any of the transaction
documents among the parties (including, among others, the distribution
agreement or the generics agreement), an impact on our earnings per share
resulting from the issuance of the Warrants, an inability to realize
anticipated benefits (including benefits resulting from participation in the
Walgreens Boots Alliance Development GmbH joint venture), the disruption of
AmerisourceBergen’s cash flow and ability to return value to its stockholders
in accordance with its past practices, disruption of or changes in vendor,
payer and customer relationships and terms, and the reduction of
AmerisourceBergen’s operational, strategic or financial flexibility; the
acquisition of businesses that do not perform as we expect or that are
difficult for us to integrate or control; our inability to successfully
complete any other transaction that we may wish to pursue from time to time;
changes in tax laws or legislative initiatives that could adversely affect our
tax positions and/or our tax liabilities or adverse resolution of challenges
to our tax positions; increased costs of maintaining, or reductions in our
ability to maintain, adequate liquidity and financing sources; volatility and
deterioration of the capital and credit markets; and other economic, business,
competitive, legal, tax, regulatory and/or operational factors affecting our
business generally. Certain additional factors that management believes could
cause actual outcomes and results to differ materially from those described in
forward-looking statements are set forth (i) in Item 1A (Risk Factors) in the
Company's Annual Report on Form 10-K for the fiscal year ended September 30,
2012 and elsewhere in that report and (ii) in other reports filed by the
Company pursuant to the Securities Exchange Act of 1934. You are cautioned not
to place undue reliance on these forward-looking statements, which speak only
as of the date they are made. Except to the extent required by law,
AmerisourceBergen does not undertake, and expressly disclaims, any duty or
obligation to publicly update any forward-looking statement after the date of
this report, whether as a result of new information, future events, changes in
assumptions or otherwise.

                                                                 
AMERISOURCEBERGEN CORPORATION
FINANCIAL SUMMARY
(In thousands, except per share data)
(unaudited)
                                                                       
                                                                       
                  Three                     Three
                  Months Ended              Months Ended
                  June 30,       % of       June 30,        % of       %
                  2013           Revenue    2012            Revenue    Change
                                                                       
Revenue           $21,906,648    100.00 %   $19,326,807     100.00 %   13.3  %
                                                                       
Cost of goods     21,344,198                18,658,941                14.4  %
sold
                                                                       
Gross profit      562,450        2.57   %   667,866         3.46   %   -15.8 %
^(1)
                                                                       
Operating
expenses:
Distribution,
selling and       331,173        1.51   %   303,812         1.57   %   9.0   %
administrative
Depreciation
and               41,138         0.19   %   35,533          0.18   %   15.8  %
amortization
Warrants ^(2)     35,815         0.16   %   -               -      %
Employee
severance,        19,678         0.09   %   4,135          0.02   %
litigation and
other, net ^(3)
Total operating   427,804        1.95   %   343,480         1.78   %   24.5  %
expenses
                                                                       
Operating         134,646        0.61   %   324,386         1.68   %   -58.5 %
income
                                                                       
Other loss        525            -      %   (4,785      )   -0.02  %
(income)
                                                                       
Interest          18,190         0.08   %   23,771         0.12   %   -23.5 %
expense, net
                                                                       
Income before     115,931        0.53   %   305,400         1.58   %   -62.0 %
income taxes
                                                                       
Income taxes      51,821         0.24   %   115,223        0.60   %   -55.0 %
                                                                       
Income from
continuing        64,110         0.29   %   190,177         0.98   %   -66.3 %
operations
                                                                       
Income (loss)
from
discontinued      104,329                   (8,906      )
operations, net
of income taxes
                                                                       
Net income        $168,439       0.77   %   $181,271       0.94   %
                                                                       
                                                                       
Basic earnings
per share:
Continuing        $0.28                     $0.75                      -62.7 %
operations
Discontinued      0.45                      (0.04       )
operations
Rounding          -                         0.01        
Total             $0.73                     $0.72       
                                                                       
Diluted
earnings per
share:
Continuing        $0.27                     $0.74                      -63.5 %
operations
Discontinued      0.44                      (0.03       )
operations
Total             $0.71                     $0.71       
                                                                       
Weighted
average common
shares
outstanding:
Basic             231,002                   252,116
Diluted ^(4)      235,669                   255,725                    -7.8  %
                                                                       

      Includes a $6.0 million gain from antitrust litigation settlements and a
(1)  $122.1 million LIFO expense charge in the three months ended June 30,
      2013. Includes a $4.7 million LIFO expense charge in the three months
      ended June 30, 2012.
(2)   Expense related to common stock warrants issued to Walgreens and
      Alliance Boots in connection with the previously announced transaction.
      Includes $1.6 million of restructuring costs and $18.1 million of
      deal-related transaction costs, primarily related to professional fees
(3)   with respect to the Walgreens / Alliance Boots transaction, in the three
      months ended June 30, 2013. Includes $4.1 million of deal-related
      transaction costs in the three months ended June 30, 2012.
      Includes the dilutive effect of stock options, restricted stock, and
(4)   restricted stock units. The Warrants were anti-dilutive in the three
      months ended June 30, 2013.
      

                                                                 
AMERISOURCEBERGEN CORPORATION
FINANCIAL SUMMARY
(In thousands, except per share data)
(unaudited)
                                                                       
                                                                       
                 Nine                       Nine
                 Months Ended               Months Ended
                 June 30,        % of       June 30,        % of       %
                 2013            Revenue    2012            Revenue    Change
                                                                       
Revenue          $63,490,127     100.00 %   $59,016,363     100.00 %   7.6   %
                                                                       
Cost of goods    61,549,860                57,095,494                7.8   %
sold
                                                                       
Gross profit     1,940,267       3.06   %   1,920,869       3.25   %   1.0   %
^(1)
                                                                       
Operating
expenses:
Distribution,
selling and      975,409         1.54   %   823,418         1.40   %   18.5  %
administrative
Depreciation
and              119,690         0.19   %   95,881          0.16   %   24.8  %
amortization
Warrants ^(2)    39,576          0.06   %   -               -      %
Employee
severance,       21,383         0.03   %   16,721         0.03   %
litigation and
other ^(3)
Total
operating        1,156,058       1.82   %   936,020         1.59   %   23.5  %
expenses
                                                                       
Operating        784,209         1.24   %   984,849         1.67   %   -20.4 %
income
                                                                       
Other loss       1,251           -      %   (4,917      )   -0.01  %
(income)
                                                                       
Interest         55,225         0.09   %   69,432         0.12   %   -20.5 %
expense, net
                                                                       
Income before    727,733         1.15   %   920,334         1.56   %   -20.9 %
income taxes
                                                                       
Income taxes     284,859        0.45   %   349,422        0.59   %   -18.5 %
                                                                       
Income from
continuing       442,874         0.70   %   570,912         0.97   %   -22.4 %
operations
                                                                       
Loss from
discontinued
operations,      (60,190     )              (15,420     )
net of income
taxes
                                                                       
Net income       $382,684       0.60   %   $555,492       0.94   %
                                                                       
                                                                       
Basic earnings
per share:
Continuing       $1.91                      $2.23                      -14.3 %
operations
Discontinued     (0.26       )              (0.06       )
operations
Total            $1.65                     $2.17       
                                                                       
Diluted
earnings per
share:
Continuing       $1.88                      $2.19                      -14.2 %
operations
Discontinued     (0.26       )              (0.06       )
operations
Rounding         0.01                      -           
Total            $1.63                     $2.13       
                                                                       
Weighted
average common
shares
outstanding:
Basic            231,273                    256,260
Diluted ^(4)     235,428                    260,404                    -9.6  %
                                                                       

      Includes a $21.7 million gain from antitrust litigation settlements and
(1)  a $123.0 million LIFO expense charge in the nine months ended June 30,
      2013. Includes a $11.4 million LIFO expense charge in the nine months
      ended June 30, 2012.
(2)   Expense related to common stock warrants issued to Walgreens and
      Alliance Boots in connection with the previously announced transaction.
      Includes $22.8 million of deal-related transaction costs, primarily
      related to professional fees with respect to the Walgreens / Alliance
      Boots transaction, and the net reversal of $(1.4) million of employee
(3)   severance and other restructuring costs in the nine months ended June
      30, 2013. Includes $6.1 million of employee severance costs and $10.6
      million of deal-related transaction costs in the nine months ended June
      30, 2012.
      Includes the dilutive effect of stock options, restricted stock, and
(4)   restricted stock units. The Warrants were anti-dilutive in the nine
      months ended June 30, 2013.
      


AMERISOURCEBERGEN CORPORATION
RECONCILIATION OF CONTINUING OPERATIONS (GAAP) TO ADJUSTED CONTINUING
OPERATIONS (NON-GAAP)
(dollars in thousands, except per share data)
(unaudited)
                                                                 
               Three Months Ended June 30, 2013
                                                         Adjusted      %
               GAAP          LIFO Expense   Warrant      Non-GAAP      Change
                                            Expense                    ^(1)
                                                                       
Revenue        $21,906,648   $-             $-           $21,906,648   13.3  %
Cost of        21,344,198    (122,077  )    -            21,222,121    13.7  %
goods sold
Gross profit   562,450       122,077        -            684,527       2.5   %
Operating      427,804       -              (35,815  )   391,989       14.1  %
expenses
Operating      134,646       122,077        35,815       292,538       -9.8  %
income
Other loss     525           -              -            525
Interest       18,190        -              -            18,190        -23.5 %
expense, net
Income
before         115,931       122,077        35,815       273,823       -10.3 %
income taxes
Income taxes   51,821        47,451         3,137        102,409       -11.1 %
^(2)
Income from
continuing     $64,110       $74,626        $32,678      $171,414      -9.9  %
operations
                                                                       
Diluted
earnings per
share from     $0.27         $0.32          $0.14        $0.73         -1.4  %
continuing
operations
                                                                       
Diluted
weighted
average        235,669       235,669        235,669      235,669       -7.8  %
common
shares
outstanding
                                                                       
                                                                       
                                                                       
                                                                       
               Nine Months Ended June 30, 2013
                                                         Adjusted      %
               GAAP          LIFO Expense   Warrant      Non-GAAP      Change
                                            Expense                    ^(1)
                                                                       
Revenue        $63,490,127   $-             $-           $63,490,127   7.6   %
Cost of        61,549,860    (123,029  )    -            61,426,831    7.6   %
goods sold
Gross profit   1,940,267     123,029        -            2,063,296     7.4   %
Operating      1,156,058     -              (39,576  )   1,116,482     19.3  %
expenses
Operating      784,209       123,029        39,576       946,814       -3.9  %
income
Other loss     1,251         -              -            1,251
Interest       55,225        -              -            55,225        -20.5 %
expense, net
Income
before         727,733       123,029        39,576       890,338       -3.3  %
income taxes
Income taxes   284,859       47,813         4,267        336,939       -3.6  %
^(2)
Income from
continuing     $442,874      $75,216        $35,309      $553,399      -3.1  %
operations
                                                                       
Diluted
earnings per
share from     $1.88         $0.32          $0.15        $2.35         7.3   %
continuing
operations
                                                                       
Diluted
weighted
average        235,428       235,428        235,428      235,428       -9.6  %
common
shares
outstanding
                                                                       

Note - No adjustments have been made to prior year GAAP continuing operations
for the three and nine month periods ended June 30, 2012.
    
(1)   Percentage change in comparison to prior year operating results, which
      do not include any non-GAAP adjustments.
      
      The income tax rate applicable to warrant expense is lower than our
      normal income tax rate as a portion of the warrant expense is not tax
(2)   deductible. The income tax rate on warrant expense will vary by quarter
      depending upon the expected quarterly changes in the fair value of the
      Warrants.
      

                                                        
AMERISOURCEBERGEN CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
                                                           
                                                           
ASSETS
                                             June 30,      September 30,
                                             2013          2012
Current assets:
Cash and cash equivalents                    $1,567,585    $1,066,608
Accounts receivable, net                     4,585,488     3,784,619
Merchandise inventories                      5,895,089     5,472,010
Prepaid expenses and other                   90,911        72,374
Assets held for sale                         -             662,853
Total current assets                         12,139,073    11,058,464
                                                           
Property and equipment, net                  777,091       743,684
Other long-term assets                       3,663,168     3,640,108
                                                           
Total assets                                 $16,579,332   $15,442,256
                                                           
                                                           
LIABILITIES AND STOCKHOLDERS' EQUITY
                                                           
Current liabilities:
Accounts payable                             $11,009,224   $9,492,589
Other current liabilities                    1,432,424     1,533,291
Liabilities held for sale                    -             239,706
Total current liabilities                    12,441,648    11,265,586
                                                           
Long-term debt                               1,396,439     1,395,931
                                                           
Other long-term liabilities                  323,051       325,897
                                                           
Stockholders' equity                         2,418,194     2,454,842
                                                           
Total liabilities and stockholders' equity   $16,579,332   $15,442,256
                                                           

                                                               
AMERISOURCEBERGEN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
                                                                  
                                                   Nine           Nine
                                                   Months Ended   Months Ended
                                                   June 30,       June 30,
                                                   2013           2012
                                                                  
Operating Activities:
Net income                                         $382,684       $555,492
Loss from discontinued operations                  60,190        15,420     
Income from continuing operations                  442,874        570,912
Adjustments to reconcile income from continuing
operations to net cash provided by operating       207,560        181,947
activities
Changes in operating assets and liabilities        84,605        138,284    
Net cash provided by operating activities -        735,039        891,143
continuing operations
Net cash provided by (used in) operating           84,025        (131,088   )
activities - discontinued operations
Net cash provided by operating activities          819,064       760,055    
                                                                  
Investing Activities:
Capital expenditures                               (137,927   )   (92,881    )
Proceeds from sales of businesses                  331,630        -
Cost of acquired companies, net of cash acquired   -              (778,755   )
Other                                              523           23         
Net cash provided by (used in) investing           194,226        (871,613   )
activities - continuing operations
Net cash used in investing activities -            (11,672    )   (34,712    )
discontinued operations
Net cash provided by (used in) investing           182,554       (906,325   )
activities
                                                                  
Financing Activities:
Net borrowings                                     -              444,290
Purchases of common stock                          (401,091   )   (514,258   )
Exercises of stock options                         132,766        91,092
Cash dividends on common stock                     (147,005   )   (100,081   )
Other                                              (34,773    )   (10,528    )
Net cash used in financing activities -            (450,103   )   (89,485    )
continuing operations
Net cash (used in) provided by financing           (50,538    )   65,513     
activities - discontinued operations
Net cash used in financing activities              (500,641   )   (23,972    )
                                                                  
Increase (decrease) in cash and cash equivalents   500,977        (170,242   )
                                                                  
Cash and cash equivalents at beginning of period   1,066,608     1,825,990  
                                                                  
Cash and cash equivalents at end of period         $1,567,585    $1,655,748 
                                                                             

                                                                           
AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION
(dollars in thousands)
(unaudited)
                                                            
                                                                           
                             Three Months Ended June 30,
Revenue                      2013               2012            % Change
                                                                           
Pharmaceutical               $21,490,543        $18,985,491     13%
Distribution
Other ^(1)                   466,710            397,452         17%
Intersegment eliminations    (50,605      )     (56,136     )   -10%
                                                                           
Revenue                      $21,906,648       $19,326,807    13%
                                                                           
                                                                           
                                                                           
                                                                           
                             Three Months Ended June 30,
Operating Income             2013               2012            % Change
                                                                           
Pharmaceutical               $165,079           $307,345        -46%
Distribution
LIFO                         122,077           -              N/M
Adjusted Pharmaceutical      287,156            307,345         -7%
Distribution
Other ^(1)                   25,060             21,176          18%
LIFO                         (122,077     )     -               N/M
Warrants                     (35,815      )     -               N/M
Employee severance,          (19,678      )     (4,135      )   N/M
litigation and other
                                                                           
Operating income             $134,646          $324,386       -58%
                                                                           
                                                                           
                                                                           
                                                                Three Months
                             Three Months Ended June 30, 2013   Ended June 30,
                                                                2012
Percentages of revenue:      GAAP               Non-GAAP        GAAP ^(2)
                                                                
Pharmaceutical
Distribution
Gross profit                 2.06         %     2.63        %   3.05        %
Operating expenses           1.30         %     1.30        %   1.44        %
Operating income             0.77         %     1.34        %   1.62        %
                                                                
Other ^(1)
Gross profit                 25.51        %     N/A             22.15       %
Operating expenses           20.14        %     N/A             16.82       %
Operating income             5.37         %     N/A             5.33        %
                                                                
AmerisourceBergen
Corporation
Gross profit                 2.57         %     3.12        %   3.46        %
Operating expenses           1.95         %     1.79        %   1.78        %
Operating income             0.61         %     1.34        %   1.68        %
                                                                

      Other for the three months ended June 30, 2013 is comprised of the
      AmerisourceBergen Consulting Services ("ABCS") operating segment and the
(1)  World Courier Group, Inc. operating segment. Other for the three months
      ended June 30, 2012 is comprised of the ABCS operating segment and the
      World Courier Group, Inc. operating segment (beginning May 1, 2012).
      
(2)   Margin percentages in the prior year period do not include any non-GAAP
      adjustments.
      

                                                                           
AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION
(dollars in thousands)
(unaudited)
                                                            
                                                                           
                              Nine Months Ended June 30,
Revenue                       2013              2012            % Change
                                                                           
Pharmaceutical                $62,300,468       $58,243,723     7%
Distribution
Other ^(1)                    1,329,984         903,178         47%
Intersegment eliminations     (140,325     )    (130,538    )   7%
                                                                           
Revenue                       $63,490,127      $59,016,363    8%
                                                                           
                                                                           
                                                                           
                                                                           
                              Nine Months Ended June 30,
Operating Income              2013              2012            % Change
                                                                           
Pharmaceutical                $774,599          $947,064        -18%
Distribution
LIFO                          123,029          -              N/M
Adjusted Pharmaceutical       897,628           947,064         -5%
Distribution
Other ^(1)                    70,569            54,506          29%
LIFO                          (123,029     )    -               N/M
Warrants                      (39,576      )    -               N/M
Employee severance,           (21,383      )    (16,721     )   N/M
litigation and other
                                                                           
Operating income              $784,209         $984,849       -20%
                                                                           
                                                                           
                                                                           
                                                                Nine Months
                              Nine Months Ended June 30, 2013   Ended June 30,
                                                                2012
Percentages of revenue:       GAAP              Non-GAAP        GAAP ^(2)
                                                                
Pharmaceutical
Distribution
Gross profit                  2.55         %    2.75        %   3.01        %
Operating expenses            1.31         %    1.31        %   1.38        %
Operating income              1.24         %    1.44        %   1.63        %
                                                                
Other ^(1)
Gross profit                  26.29        %    N/A             18.71       %
Operating expenses            20.98        %    N/A             12.68       %
Operating income              5.31         %    N/A             6.03        %
                                                                
AmerisourceBergen
Corporation
Gross profit                  3.06         %    3.25        %   3.25        %
Operating expenses            1.82         %    1.76        %   1.59        %
Operating income              1.24         %    1.49        %   1.67        %
                                                                

      Other for the nine months ended June 30, 2013 is comprised of the
      AmerisourceBergen Consulting Services ("ABCS") operating segment and the
(1)  World Courier Group, Inc. operating segment. Other for the nine months
      ended June 30, 2012 is comprised of the ABCS operating segment and the
      World Courier Group, Inc. operating segment (beginning May 1, 2012).
      
(2)   Margin percentages in the prior year period do not include any non-GAAP
      adjustments.
      

Contact:

AmerisourceBergen Corporation
Barbara Brungess, 610-727-7199
bbrungess@amerisourcebergen.com
 
Press spacebar to pause and continue. Press esc to stop.